Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Operating Income (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Operating Income for 6 consecutive years, with -$42.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income fell 46.1% to -$42.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$157.7 million, a 59.51% decrease, with the full-year FY2025 number at -$157.7 million, down 59.51% from a year prior.
  • Operating Income was -$42.4 million for Q4 2025 at Janux Therapeutics, down from -$35.3 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$2.3 million in Q1 2021 to a low of -$45.1 million in Q2 2025.
  • A 5-year average of -$21.5 million and a median of -$18.1 million in 2022 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: plummeted 768.07% in 2021, then skyrocketed 33.38% in 2024.
  • Janux Therapeutics' Operating Income stood at -$13.5 million in 2021, then plummeted by 35.4% to -$18.3 million in 2022, then grew by 11.66% to -$16.1 million in 2023, then tumbled by 79.85% to -$29.0 million in 2024, then plummeted by 46.1% to -$42.4 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Operating Income are -$42.4 million (Q4 2025), -$35.3 million (Q3 2025), and -$45.1 million (Q2 2025).